Anti-Corruption in China Healthcare – the Impact and the Outlook
The share prices of China healthcare are now plummeting due to anti-corruption campaign, which will reach a climax in 23H2 (We'll post updates in...
771 Views
Lu DaoPei Medical Group Pre-IPO - Ramp up in Progress but Looks Promising
Lu Daopei Medical Group (1816743D CH) is looking to raise around US$400m in its upcoming Hong Kong IPO. LDPM has supported its growth through its...
396 Views
Shanghai Haohai Biological Technology (688366.CH/6826.HK)- Disappointing Earnings and Gloomy Outlook
Continuous M&A fails to bring ideal performance to Haohai. Medical aesthetics is the main growth driver, but Haohai is lack of competitiveness....
418 Views
Huadong Medicine (000963.CH) 2022H1 - Huadong Is Back on Track. If Shares Pullback, Then Be Long
Huadong released encouraging H1 results.It's back on track. This positive momentum will continue in H2, especially medical cosmetology and...
328 Views
China Healthcare Weekly (Aug.12)-AI Drug Discovery, License-In Mode Valuation, Pet Medical Equipment
AI drug discovery is far from meeting the current investment level and expectations. The success of license-in mode must be based on appropriate...
390 Views